Overview

Evaluation of the Immunopharmacology of EDP1815 and EDP2939

Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
A single-center, randomized, double-blind, placebo-controlled, multiple dose platform trial.
Phase:
Phase 1
Details
Lead Sponsor:
Evelo Biosciences, Inc.